Management of Atrial Flutter: Medications and Procedures

Atrial flutter is a type of arrhythmia that can be managed through various medications and procedures. The first step in treatment is to control the ventricular rate, which can be achieved through the administration of beta-blockers or rate-limiting calcium-channel blockers. For patients with diabetes mellitus, cardio-selective beta-blockers such as atenolol, bisoprolol, metoprolol, and nebivolol are preferred.

Amiodarone is not the first-line treatment for atrial flutter and is mainly used for ventricular tachycardias and chemical cardioversion in atrial fibrillation. Propranolol can be used for rate control, but cardio-selective beta-blockers are preferred for patients with diabetes mellitus.

Synchronised direct-current (DC) cardioversion is the first-line treatment for patients with haemodynamic instability caused by a tachyarrhythmia. However, if the patient exhibits no adverse signs, DC cardioversion is not indicated. Unsynchronised DC cardioversion is only given in cases of ventricular fibrillation.

All patients should be assessed for their risk of stroke and the need for thromboprophylaxis, with the choice of anticoagulant based on scoring criteria such as CHA2DS2-VASc. Overall, the management of atrial flutter involves a tailored approach based on the individual patient’s needs and medical history.

The symptoms of pruritus and pain that gradually worsen, along with the results of the examination, indicate a high likelihood of post-thrombotic syndrome.

Post-Thrombotic Syndrome: A Complication of Deep Vein Thrombosis

Post-thrombotic syndrome is a clinical syndrome that may develop following a deep vein thrombosis (DVT). It is caused by venous outflow obstruction and venous insufficiency, which leads to chronic venous hypertension. Patients with post-thrombotic syndrome may experience painful, heavy calves, pruritus, swelling, varicose veins, and venous ulceration.

In the past, compression stockings were offered to patients with DVT to reduce the risk of post-thrombotic syndrome. However, current recommendations state that elastic graduated compression stockings should not be used to prevent post-thrombotic syndrome or VTE recurrence after a proximal DVT. This recommendation does not cover the use of elastic stockings for the management of leg symptoms after DVT.

Once post-thrombotic syndrome has developed, compression stockings are a recommended treatment. Other recommendations include keeping the leg elevated. It is important for healthcare providers to recognize the potential complications of DVT and to provide appropriate management to prevent the development of post-thrombotic syndrome.

NICE guidelines recommend that patients with peripheral arterial disease should be treated with clopidogrel and atorvastatin. This patient is experiencing intermittent claudication, which is a symptom of peripheral vascular disease caused by atherosclerosis. It is important to differentiate this from critical limb ischaemia, which is characterised by pain at rest. An ankle-brachial pressure index of < 0.9 suggests PAD, with an index < 0.5 suggesting critical limb ischaemia. This patient has several risk factors, including smoking, hypertension and obesity. Aspirin is not the first-line antiplatelet for PAD and should only be used if clopidogrel is not tolerated. Low molecular weight heparin is indicated for deep vein thrombosis, which is characterised by unilateral calf pain and swelling with tenderness along the deep venous system. Metformin is indicated for diabetes mellitus, which cannot be diagnosed without a HbA1c or blood glucose reading. Regular glucose checks are recommended for patients with vascular risk factors. Peripheral arterial disease (PAD) is a condition that is strongly associated with smoking. Therefore, patients who still smoke should be provided with assistance to quit smoking. It is also important to treat any comorbidities that the patient may have, such as hypertension, diabetes mellitus, and obesity. All patients with established cardiovascular disease, including PAD, should be taking a statin, with Atorvastatin 80 mg being the recommended dosage. In 2010, NICE published guidance recommending the use of clopidogrel as the first-line treatment for PAD patients instead of aspirin. Exercise training has also been shown to have significant benefits, and NICE recommends a supervised exercise program for all PAD patients before other interventions. For severe PAD or critical limb ischaemia, there are several treatment options available. Endovascular revascularization and percutaneous transluminal angioplasty with or without stent placement are typically used for short segment stenosis, aortic iliac disease, and high-risk patients. On the other hand, surgical revascularization, surgical bypass with an autologous vein or prosthetic material, and endarterectomy are typically used for long segment lesions, multifocal lesions, lesions of the common femoral artery, and purely infrapopliteal disease. Amputation should only be considered for patients with critical limb ischaemia who are not suitable for other interventions such as angioplasty or bypass surgery. There are also drugs licensed for use in PAD, including naftidrofuryl oxalate, a vasodilator sometimes used for patients with a poor quality of life. Cilostazol, a phosphodiesterase III inhibitor with both antiplatelet and vasodilator effects, is not recommended by NICE.

If a patient has a Wells’ score of 1 or less for a suspected DVT, the first step is to arrange a D dimer test with results available within 4 hours, according to NICE guidelines. In this case, the score of 1 is due to localized tenderness along the deep venous system, with no other risk factors present. A proximal leg vein ultrasound scan is not the first-line investigation option for a Wells’ score of 1 or less, and anticoagulant treatment should not be started without a D dimer test. If the D dimer results cannot be obtained within 4 hours, low molecular weight heparin injection may be considered, but therapeutic dose apixaban should not be started without a D dimer test.

NICE updated their guidelines on the investigation and management of venous thromboembolism (VTE) in 2020. The use of direct oral anticoagulants (DOACs) is recommended as first-line treatment for most people with VTE, including as interim anticoagulants before a definite diagnosis is made. Routine cancer screening is no longer recommended following a VTE diagnosis. The cornerstone of VTE management is anticoagulant therapy, with DOACs being the preferred choice. All patients should have anticoagulation for at least 3 months, with the length of anticoagulation being determined by whether the VTE was provoked or unprovoked.

Understanding Anticoagulation Treatment for Atrial Fibrillation: A CHADS-VASc Scoring System Overview

Atrial fibrillation (AF) is a common rhythm disturbance that can increase the risk of stroke. To determine the appropriate treatment for primary prevention of stroke, healthcare professionals use the CHADS-VASc scoring system. This system assigns points based on various risk factors, including age, sex, hypertension, diabetes, previous stroke or transient ischemic attack, and vascular disease.

This score is based on a point system in which 2 points are assigned for a history of stroke or transient ischemic attack or age 75 years or more and 1 point each is assigned for age 65 to 74 years; a history of hypertension, diabetes, recent cardiac failure, vascular disease (myocardial infarction, complex aortic plaque, and peripheral arterial disease (PAD), including prior revascularization, amputation due to PAD, or angiographic evidence of PAD, etc.); and female gender, resulting in a maximum score of 9 points.

Aspirin is not recommended for primary prevention of stroke in patients with AF, but may be used for secondary prevention after a stroke. Clexane, a low-molecular-weight heparin, is not used for long-term treatment of AF. Dipyridamole may be used in combination with clopidogrel or aspirin for stroke treatment, but not for prevention in AF patients.

It is important to accurately identify AF and assess the patient’s risk using the CHADS-VASc scoring system to determine the appropriate anticoagulation treatment. NOACs are only licensed for non-valvular AF, so patients with valvular AF should be treated with warfarin or seek advice from a specialist.

Regardless of age, ACE inhibitors/A2RBs are the first-line treatment for hypertension in diabetics.

Blood Pressure Management in Diabetes Mellitus

Patients with diabetes mellitus have traditionally been managed with lower blood pressure targets to reduce their overall cardiovascular risk. However, a 2013 Cochrane review found that there was little difference in outcomes between patients who had tight blood pressure control (targets < 130/85 mmHg) and those with more relaxed control (< 140-160/90-100 mmHg), except for a slightly reduced rate of stroke in the former group. As a result, NICE recommends a blood pressure target of < 140/90 mmHg for type 2 diabetics, the same as for patients without diabetes. For patients with type 1 diabetes, NICE recommends a blood pressure target of 135/85 mmHg unless they have albuminuria or two or more features of metabolic syndrome, in which case the target should be 130/80 mmHg. ACE inhibitors or angiotensin-II receptor antagonists (A2RBs) are the first-line antihypertensive regardless of age, as they have a renoprotective effect in diabetes. A2RBs are preferred for black African or African-Caribbean diabetic patients. Further management then follows that of non-diabetic patients. It is important to note that autonomic neuropathy may result in more postural symptoms in patients taking antihypertensive therapy. Therefore, the routine use of beta-blockers in uncomplicated hypertension should be avoided, particularly when given in combination with thiazides, as they may cause insulin resistance, impair insulin secretion, and alter the autonomic response to hypoglycemia.

Infective endocarditis is a serious infection of the heart lining and valves. The 2008 guidelines from NICE have changed the list of procedures for which antibiotic prophylaxis is recommended. According to NICE, dental procedures, gastrointestinal, genitourinary, and respiratory tract procedures do not require prophylaxis. However, if a person at risk of infective endocarditis is receiving antimicrobial therapy because they are undergoing a gastrointestinal or genitourinary procedure at a site where there is a suspected infection, they should be given an antibiotic that covers organisms that cause infective endocarditis. It is important to note that these recommendations differ from the American Heart Association/European Society of Cardiology guidelines, which still advocate antibiotic prophylaxis for high-risk patients undergoing dental procedures.

The guidelines suggest that any episodes of infection in people at risk of infective endocarditis should be investigated and treated promptly to reduce the risk of endocarditis developing. It is crucial to follow these guidelines to prevent the development of infective endocarditis, which can lead to severe complications and even death. It is also important to note that these guidelines may change over time as new research and evidence become available. Therefore, healthcare professionals should stay up-to-date with the latest recommendations to provide the best possible care for their patients.

During advanced ALS, the recommended dose of adrenaline to administer is 1mg. If the patient is identified in the hospital, they should receive a minimum shock of 150 joules (unless the defibrillator model specifies otherwise). Compressions at a rate of 30:2 should be resumed for 2 minutes, followed by reassessment of the rhythm. If VF or pVT persists, a second shock should be given. Repeat the previous steps until the third shock, at which point 1mg IV of adrenaline and 300 mg IV of amiodarone should be administered while continuing CPR. Afterward, 1mg of adrenaline should be given after every other shock. Consider administering a second dose of amiodarone after a total of 5 defibrillation attempts if it is available. If amiodarone is not available, lidocaine can be used.

The 2015 Resus Council guidelines for adult advanced life support outline the steps to be taken when dealing with patients with shockable and non-shockable rhythms. For both types of patients, chest compressions are a crucial part of the process, with a ratio of 30 compressions to 2 ventilations. Defibrillation is recommended for shockable rhythms, with a single shock for VF/pulseless VT followed by 2 minutes of CPR. Adrenaline and amiodarone are the drugs of choice for non-shockable rhythms, with adrenaline given as soon as possible and amiodarone administered after 3 shocks for VF/pulseless VT. Thrombolytic drugs should be considered if a pulmonary embolus is suspected. Atropine is no longer recommended for routine use in asystole or PEA. Oxygen should be titrated to achieve saturations of 94-98% following successful resuscitation. The Hs and Ts should be considered as potential reversible causes of cardiac arrest.

Drug Management for Chronic Heart Failure: NICE Guidelines

Chronic heart failure is a serious condition that requires proper management to improve patient outcomes. In 2018, the National Institute for Health and Care Excellence (NICE) updated their guidelines on drug management for chronic heart failure. The guidelines recommend first-line therapy with both an ACE-inhibitor and a beta-blocker, with clinical judgement used to determine which one to start first. Second-line therapy involves the use of aldosterone antagonists, which should be monitored for hyperkalaemia. SGLT-2 inhibitors are also increasingly being used to manage heart failure with a reduced ejection fraction. Third-line therapy should be initiated by a specialist and may include ivabradine, sacubitril-valsartan, hydralazine in combination with nitrate, digoxin, or cardiac resynchronisation therapy. Other treatments such as annual influenza and one-off pneumococcal vaccines are also recommended.

Overall, the NICE guidelines provide a comprehensive approach to drug management for chronic heart failure. It is important to note that loop diuretics have not been shown to reduce mortality in the long-term, and that ACE-inhibitors and beta-blockers have no effect on mortality in heart failure with preserved ejection fraction. Healthcare professionals should carefully consider the patient’s individual needs and circumstances when determining the appropriate drug therapy for chronic heart failure.

For a newly diagnosed patient with hypertension and a history of type 2 diabetes mellitus, it is recommended to add an ACE inhibitor or an angiotensin receptor blocker regardless of age. In this case, Ramipril, an ACE inhibitor, would be the appropriate choice. However, if the patient did not have a history of type 2 diabetes, the initial management would be to prescribe a calcium channel blocker such as amlodipine, especially if the patient is over 55 years old. If the blood pressure remains high, a thiazide-like diuretic or calcium channel blocker can be added to the ACE inhibitor. If the blood pressure still remains elevated, a combination of ACE inhibitor, calcium channel blocker, and thiazide-like diuretic can be considered. Indapamide is a thiazide-like diuretic that can be used in combination with an ACE inhibitor or as an additional therapy with an ACE inhibitor and calcium channel blocker if the blood pressure is not well controlled. Bisoprolol, a beta-blocker, can also be considered if the blood pressure remains high despite the combination of ACE inhibitor, calcium channel blocker, and thiazide-like diuretic.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

Anticoagulation should be continued long-term, even if sinus rhythm is maintained, following elective DC cardioversion for AF in high-risk patients. The correct answer is to continue anticoagulation lifelong, with regular evaluation of bleeding risk. The options of continuing anticoagulation for 4 weeks or 6 months then stopping are incorrect for this patient who has a high CHAD-VASC score. One week of low molecular weight heparin is not the appropriate answer in this case, although it may be used for thromboprophylaxis in some post-surgical patients.

Atrial Fibrillation and Cardioversion: Elective Procedure for Rhythm Control

Cardioversion is a medical procedure used in atrial fibrillation (AF) to restore the heart’s normal rhythm. There are two scenarios where cardioversion may be used: as an emergency if the patient is haemodynamically unstable, or as an elective procedure where a rhythm control strategy is preferred. In the elective scenario, cardioversion can be performed either electrically or pharmacologically. Electrical cardioversion is synchronised to the R wave to prevent delivery of a shock during the vulnerable period of cardiac repolarisation when ventricular fibrillation can be induced.

According to the 2014 NICE guidelines, rate or rhythm control should be offered if the onset of the arrhythmia is less than 48 hours, and rate control should be started if it is more than 48 hours or is uncertain. If the AF is definitely of less than 48 hours onset, patients should be heparinised and may be cardioverted using either electrical or pharmacological means. However, if the patient has been in AF for more than 48 hours, anticoagulation should be given for at least 3 weeks prior to cardioversion. An alternative strategy is to perform a transoesophageal echo (TOE) to exclude a left atrial appendage (LAA) thrombus. If excluded, patients may be heparinised and cardioverted immediately.

NICE recommends electrical cardioversion in this scenario, rather than pharmacological. If there is a high risk of cardioversion failure, it is recommended to have at least 4 weeks of amiodarone or sotalol prior to electrical cardioversion. Following electrical cardioversion, patients should be anticoagulated for at least 4 weeks. After this time, decisions about anticoagulation should be taken on an individual basis depending on the risk of recurrence.

First-degree heart block is a common occurrence in athletes and does not require any intervention. This patient’s ECG shows a prolonged PR interval, which is the defining characteristic of first-degree heart block. As it is a normal variant, there is no need for any referral or further investigations. The patient can continue to play football without any concerns.

Normal Variants in Athlete ECGs

Athletes may exhibit certain ECG changes that are considered normal variants. These include sinus bradycardia, junctional rhythm, first degree heart block, and Mobitz type 1 (Wenckebach phenomenon). Sinus bradycardia refers to a slower than normal heart rate originating from the sinus node, which is the natural pacemaker of the heart. Junctional rhythm occurs when the heart’s electrical impulses originate from the junction between the atria and ventricles, rather than the sinus node. First degree heart block is a delay in the electrical conduction between the atria and ventricles, resulting in a prolonged PR interval on the ECG. Mobitz type 1, also known as Wenckebach phenomenon, is a type of heart block where there is a progressive lengthening of the PR interval until a beat is dropped. These ECG changes are considered normal in athletes and do not necessarily indicate any underlying cardiac pathology.

The left main coronary artery is not the cause of heart block. It usually results in anterior myocardial infarction.

Understanding Heart Blocks and their Features

Heart blocks are a type of cardiac conduction disorder that can lead to a range of symptoms and complications. There are three types of heart blocks, each with distinct features and characteristics. First-degree heart block is characterized by a prolonged PR interval, while second-degree heart block can be further divided into two subtypes: Mobitz I and Mobitz II. Mobitz I is characterized by a progressive prolongation of the PR interval until a dropped beat occurs, while Mobitz II is characterized by a constant PR interval but often not followed by a QRS complex.

The most severe form of heart block is third-degree or complete heart block, which is characterized by a complete dissociation between the P waves and QRS complexes. This can lead to a range of symptoms, including syncope, heart failure, regular bradycardia, and wide pulse pressure. Other features of complete heart block include cannon waves in the neck and variable intensity of S1.

The National Institute for Health and Care Excellence recommends using a β blocker or calcium channel blocker as the first-line treatment for angina, along with a statin. If a patient is intolerant to β blockers or not responding to a CCB alone, a long-acting nitrate can be added. An ACE inhibitor is not indicated for angina treatment. Beta blockers and CCBs can be used together if one alone does not control symptoms, but caution is needed to avoid conduction problems. Long-acting nitrates should only be used in isolation if CCB or β blocker use is contraindicated. Aspirin is recommended for secondary prevention, and short-acting nitrates can be used for symptom relief. The 4S study showed that statins significantly reduce the risk of MI in patients with angina and high cholesterol levels.

Regardless of age, ACE inhibitors/A2RBs are the first-line treatment for hypertension in diabetics.

Blood Pressure Management in Diabetes Mellitus

Patients with diabetes mellitus have traditionally been managed with lower blood pressure targets to reduce their overall cardiovascular risk. However, a 2013 Cochrane review found that there was little difference in outcomes between patients who had tight blood pressure control (targets < 130/85 mmHg) and those with more relaxed control (< 140-160/90-100 mmHg), except for a slightly reduced rate of stroke in the former group. As a result, NICE recommends a blood pressure target of < 140/90 mmHg for type 2 diabetics, the same as for patients without diabetes. For patients with type 1 diabetes, NICE recommends a blood pressure target of 135/85 mmHg unless they have albuminuria or two or more features of metabolic syndrome, in which case the target should be 130/80 mmHg. ACE inhibitors or angiotensin-II receptor antagonists (A2RBs) are the first-line antihypertensive regardless of age, as they have a renoprotective effect in diabetes. A2RBs are preferred for black African or African-Caribbean diabetic patients. Further management then follows that of non-diabetic patients. It is important to note that autonomic neuropathy may result in more postural symptoms in patients taking antihypertensive therapy. Therefore, the routine use of beta-blockers in uncomplicated hypertension should be avoided, particularly when given in combination with thiazides, as they may cause insulin resistance, impair insulin secretion, and alter the autonomic response to hypoglycemia.

Bedside Abdominal Ultrasound for Ruptured Abdominal Aortic Aneurysm: Diagnosis and Management

This patient is likely experiencing a ruptured abdominal aortic aneurysm (AAA), a life-threatening medical emergency. Bedside abdominal ultrasound (US) is the best initial diagnostic test for ruling out AAA as a cause of abdominal or back pain, as it provides an instant, objective measurement of aortic diameter. An AAA is a dilatation of the abdominal aorta greater than 3 cm in diameter, with a significant risk of rupture at diameters greater than 5 cm. Risk factors for AAA include smoking and co-existing vascular disease. Symptoms of a ruptured AAA include pain, cardiovascular failure, and distal ischemia. Once diagnosed, a CT angiogram is the gold-standard imaging for planning surgery to repair the aneurysm. Endoscopic retrograde cholangiopancreatography and liver function tests are not indicated in this case, while serum amylase or lipase should be measured in all patients presenting with acute abdominal or upper back pain to exclude acute pancreatitis as a differential diagnosis.

For reducing the risk of stroke in patients with atrial fibrillation (AF), the first-line anticoagulation should be a direct oral anticoagulant (DOAC) such as rivaroxaban. This recommendation is based on a scenario where a patient is found to have AF during a wellbeing check and requires anticoagulation due to the increased risk of thrombosis. Aspirin is not the correct choice as it is an antiplatelet and not an anticoagulant. While dalteparin and enoxaparin are low molecular weight heparins that are often used for VTE prophylaxis, DOACs are preferred first-line for stroke risk reduction in AF. Patients often prefer DOACs as they are available in tablet form.

NICE recommends using the CHA2DS2-VASc score to determine the need for anticoagulation in patients with any history of AF. The ORBIT scoring system should be used to assess bleeding risk, but anticoagulation should not be withheld solely on the grounds of age or risk of falls. DOACs are now recommended as the first-line anticoagulant for patients with AF, with warfarin used second-line if a DOAC is contraindicated or not tolerated. Aspirin is not recommended for reducing stroke risk in patients with AF.

In cases of haemodynamically stable patients with SVT who do not respond to vagal manoeuvres, the recommended course of action is to administer adenosine.

Understanding Supraventricular Tachycardia

Supraventricular tachycardia (SVT) is a type of tachycardia that originates above the ventricles. It is commonly associated with paroxysmal SVT, which is characterized by sudden onset of a narrow complex tachycardia, usually an atrioventricular nodal re-entry tachycardia (AVNRT). Other causes include atrioventricular re-entry tachycardias (AVRT) and junctional tachycardias.

When it comes to acute management, vagal maneuvers such as the Valsalva maneuver or carotid sinus massage can be used. Intravenous adenosine is also an option, with a rapid IV bolus of 6mg given initially, followed by 12mg and then 18mg if necessary. However, adenosine is contraindicated in asthmatics, and verapamil may be a better option for them. Electrical cardioversion is another option.

To prevent episodes of SVT, beta-blockers can be used. Radio-frequency ablation is also an option. It is important to work with a healthcare provider to determine the best course of treatment for each individual case.

Overall, understanding SVT and its management options can help individuals with this condition better manage their symptoms and improve their quality of life.

If a patient in this age group has poorly controlled hypertension despite taking an ACE inhibitor (or angiotensin II receptor blocker), the next step is to consider adding a calcium channel blocker or a thiazide-like diuretic. In this case, adding a calcium channel blocker would be the appropriate choice. Beta blockers are not recommended in the NICE guidelines for hypertension management. While a thiazide-like diuretic could also be an option, furosemide, a loop diuretic, is not suitable. It is important to note that adding another ACE inhibitor is not recommended since the patient is already taking one.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

Differential Diagnosis for Familial Primary Pulmonary Hypertension

Familial primary pulmonary hypertension is a rare condition that presents with breathlessness, fatigue, angina, or syncope. It has an autosomal dominant pattern of inheritance with incomplete penetrance and physical signs such as elevated JVP, left parasternal heave, pansystolic murmur, right ventricular S4, and peripheral edema. Without treatment, average survival is less than three years. While tricuspid regurgitation may be present, it is best explained in the context of a diagnosis of familial primary pulmonary hypertension. Chronic pulmonary thromboembolism is a more common differential diagnosis that should be considered. Constrictive pericarditis and pulmonary venous hypertension are unlikely diagnoses as they do not run in families. Clinical management requires a specialist with considerable expertise in the field.